Company intelligence / Profile preview

ALCADIA

San Diego, California, United Statesalcadia.fr ↗

Ownership: Private
Employees: ~700
Development stage: Other

Overview

Acadia Pharmaceuticals has commercialized Nuplazid (pimavanserin) for Parkinson's disease psychosis and Daybue (trofinetide) for Rett syndrome. The company continues to develop therapies targeting high unmet needs in CNS disorders including schizophrenia, major depressive disorder, dementia-related psychosis, Prader-Willi syndrome, and neuropsychiatric symptoms associated with various neurological conditions. Recent clinical progress includes expansion into new indications and licensing of additional assets such as SAN711 for essential tremor.

Therapeutic areas: PsychiatryRare DiseasesNeurology
Modalities: Small moleculePeptidesBiologic
Industry: Biotech

Partnerships

Recent global license from Saniona for SAN711historical collaborations with Allergan

Beyond the preview

Go deeper on ALCADIA.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ALCADIA.

Explore the full profile